Tempest Therapeutics Stock (NASDAQ:TPST)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$7.76

52W Range

$5.36 - $28.34

50D Avg

$6.94

200D Avg

$9.95

Market Cap

$33.03M

Avg Vol (3M)

$125.25K

Beta

-2.30

Div Yield

-

TPST Company Profile


Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

24

IPO Date

Nov 12, 2012

Website

TPST Performance


TPST Financial Summary


Dec 24Dec 23Dec 22
Revenue---
Operating Income-$-29.16M$-34.64M
Net Income$-41.84M$-29.49M$-36.78M
EBITDA-$-28.78M$-32.28M
Basic EPS$-1.50$-1.91$-3.18
Diluted EPS$-1.50$-1.91$-3.18

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison


TickerCompany
RNAZTransCode Therapeutics, Inc.
ERASErasca, Inc.
VRPXVirpax Pharmaceuticals, Inc.
INDPIndaptus Therapeutics, Inc.
RNXTRenovoRx, Inc.
MDIAMediaCo Holding Inc.
FBRXForte Biosciences, Inc.